HER-2/neu is rate-limiting for ovarian cancer growth. Conditional depletion of HER-2/neu by ribozyme targeting. (Q54151898)

25 May 2018

title

HER-2/neu is rate-limiting for ovarian cancer growth. Conditional depletion of HER-2/neu by ribozyme targeting. (English)

1 reference

25 May 2018

1 reference

3

1 reference

25 May 2018

author name string

Juhl H

series ordinal

1

1 reference

25 May 2018

Downing SG

series ordinal

2

1 reference

25 May 2018

Czubayko F

series ordinal

4

1 reference

25 May 2018

language of work or name

English

0 references

publication date

1 November 1997

1 reference

25 May 2018

Journal of Biological Chemistry

number of pages

5

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

25 May 2018

volume

272

1 reference

25 May 2018

issue

47

1 reference

25 May 2018

page(s)

29482-29486

1 reference

25 May 2018

Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185.

cites work

1 reference

https://api.crossref.org/works/10.1074%2FJBC.272.47.29482

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.272.47.29482

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.272.47.29482

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.272.47.29482

Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.272.47.29482

Ribozymes as human therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.272.47.29482

Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.272.47.29482

Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.272.47.29482

Tight control of gene expression in mammalian cells by tetracycline-responsive promoters

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.272.47.29482

Steroid hormonal independence of HER-2/neu mRNA expression in four human ovarian carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.272.47.29482

Human trophoblast and choriocarcinoma expression of the growth factor pleiotrophin attributable to germ-line insertion of an endogenous retrovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.272.47.29482

Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.272.47.29482

Potent antitumour activity of a new class of tumour-specific killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.272.47.29482

Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.272.47.29482

21 January 2018

Identifiers

DOI

10.1074/JBC.272.47.29482

1 reference

25 May 2018

PubMed ID

9368008

1 reference

25 May 2018